Nasdaq · CIK 0001515673
RARE Ultragenyx Pharmaceutical Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $15.48 on Oct 9, 2026, +20% from the 52-week low and -58% from the high.
Last 90 days
Net insider value
-$20k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$20k by 1 insider
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
RAREOct 9, 2026 · close 15.48
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Ultragenyx Pharmaceutical Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Theodore Alan Huizenga SVP, Chief Accounting Officer sell | $17k 1,283 shares | -2% | - | |
| 15Weak | Theodore Alan Huizenga SVP, Chief Accounting Officer sell | $2,252 161 shares | -0% | - | |
| 20Weak | Eric Crombez EVP and Chief Medical Officer sell | $29k 762 shares | -1% | +14% from low-40% from high | |
| 45Moderate | Howard Horn Chief Financial Officer sell | $72k 1,785 shares | -2% | - | |
| 51Moderate | Eric Crombez EVP and Chief Medical Officer sell | $377k 8,945 shares | -11% | - | |
| 55Moderate | Erik Harris EVP & Chief Commercial Officer sell | $636k 15,103 shares | -15% | - | |
| 36Weak | Theodore Alan Huizenga SVP, Chief Accounting Officer sell | $41k 967 shares | -2% | - | |
| 45Moderate | Emil D Kakkis President & CEO sell | $4.2M 98,434 shares | -5% | - | |
| 43Moderate | Thomas Richard Kassberg CBO & EVP sell | $254k 6,028 shares | -2% | - | |
| 23Weak | Emil D Kakkis President & CEO sell | $495k 11,727 shares | -1% | - | |
| 21Weak | Emil D Kakkis President & CEO sell | $414k 8,273 shares | -0% | - | |
| 38Weak | Howard Horn Chief Financial Officer sell | $394k 7,465 shares | -7% | - |
Congressional trades
4 trades in RARE disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $1,001 to $15k | Mar 3 / Apr 7 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $1,001 to $15k | Feb 18 / Mar 9 19 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $1,001 to $15k | Aug 8, 2025 / Sep 12, 2025 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $1,001 to $15k | Jul 15, 2025 / Aug 14, 2025 30 days after the trade | Clerk |
Transactions
The last 40 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Theodore Alan Huizenga SVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,283 | $13.57 | $17k | 67,863 | 27 d ago |
| Sep 3, 2026 | Theodore Alan Huizenga SVP, Chief Accounting Officer | SOpen-market sale Common Stock | -161 | $13.99 | $2,252 | 69,146 | 34 d ago |
| May 15, 2025 | Deborah Dunsire director | AGrant or award Common Stock | +5,740 | $0.00 | $0 | 30,815 | May 19, 2025 |
| May 15, 2025 | Matthew K Fust director | AGrant or award Common Stock | +5,740 | $0.00 | $0 | 25,945 | May 19, 2025 |
| May 15, 2025 | Deborah Dunsire director | AGrant or award Stock Option (Right to Buy)derivative | +10,787 | $0.00 | $0 | 10,787 | May 19, 2025 |
| May 15, 2025 | Matthew K Fust director | AGrant or award Stock Option (Right to Buy)derivative | +10,787 | $0.00 | $0 | 10,787 | May 19, 2025 |
| Apr 21, 2025 | Eric Crombez EVP and Chief Medical Officer | SOpen-market sale Common Stock | -242 | $35.11 | $8,497 | 71,680 | May 5, 2025 |
| May 5, 2025 | Eric Crombez EVP and Chief Medical Officer | SOpen-market sale Common Stock | -520 | $39.24 | $20k | 71,530 | May 5, 2025 |
| Mar 6, 2025 | Howard Horn Chief Financial Officer | SOpen-market sale Common Stock | -1,785 | $40.40 | $72k | 106,169 | Mar 10, 2025 |
| Mar 1, 2025 | Erik Harris EVP & Chief Commercial Officer | AGrant or award Common Stock | +16,813 | $0.00 | $0 | 83,976 | Mar 4, 2025 |
| Mar 1, 2025 | Thomas Richard Kassberg CBO & EVP | AGrant or award Common Stock | +18,443 | $0.00 | $0 | 271,266 | Mar 4, 2025 |
| Mar 1, 2025 | Emil D Kakkis President & CEO | AGrant or award Common Stock10b5-1 | +43,268 | $0.00 | $0 | 607,873 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore Alan Huizenga SVP, Chief Accounting Officer | AGrant or award Common Stock | +9,392 | $0.00 | $0 | 51,232 | Mar 4, 2025 |
| Mar 1, 2025 | Dennis Karl Huang See Remarks | AGrant or award Common Stock | +14,494 | $0.00 | $0 | 97,496 | Mar 4, 2025 |
| Mar 1, 2025 | Howard Horn Chief Financial Officer | AGrant or award Common Stock | +15,653 | $0.00 | $0 | 107,954 | Mar 4, 2025 |
| Mar 1, 2025 | Eric Crombez EVP and Chief Medical Officer | AGrant or award Common Stock | +16,813 | $0.00 | $0 | 65,244 | Mar 4, 2025 |
| Mar 3, 2025 | Thomas Richard Kassberg CBO & EVP | SOpen-market sale Common Stock | -6,028 | $42.10 | $254k | 265,238 | Mar 4, 2025 |
| Mar 1, 2025 | Eric Crombez EVP and Chief Medical Officer | AGrant or award Common Stock | +14,971 | $0.00 | $0 | 80,215 | Mar 4, 2025 |
| Mar 1, 2025 | Emil D Kakkis President & CEO | AGrant or award Common Stock10b5-1 | +107,292 | $0.00 | $0 | 715,165 | Mar 4, 2025 |
| Mar 1, 2025 | Erik Harris EVP & Chief Commercial Officer | AGrant or award Common Stock | +18,443 | $0.00 | $0 | 102,419 | Mar 4, 2025 |
| Mar 1, 2025 | Howard Horn Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +28,160 | $0.00 | $0 | 28,160 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore Alan Huizenga SVP, Chief Accounting Officer | SOpen-market sale Common Stock | -967 | $42.10 | $41k | 50,265 | Mar 4, 2025 |
| Mar 1, 2025 | Dennis Karl Huang See Remarks | AGrant or award Common Stock | +18,443 | $0.00 | $0 | 115,939 | Mar 4, 2025 |
| Mar 3, 2025 | Dennis Karl Huang See Remarks | FTax withholding Common Stock | -1,348 | $42.92 | $58k | 114,591 | Mar 4, 2025 |
| Mar 3, 2025 | Eric Crombez EVP and Chief Medical Officer | SOpen-market sale Common Stock | -8,945 | $42.10 | $377k | 71,922 | Mar 4, 2025 |
| Mar 3, 2025 | Erik Harris EVP & Chief Commercial Officer | SOpen-market sale Common Stock | -15,103 | $42.10 | $636k | 87,855 | Mar 4, 2025 |
| Mar 3, 2025 | Thomas Richard Kassberg CBO & EVP | FTax withholding Common Stock | -508 | $42.92 | $22k | 264,730 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore Alan Huizenga SVP, Chief Accounting Officer | FTax withholding Common Stock | -141 | $42.92 | $6,052 | 50,124 | Mar 4, 2025 |
| Mar 3, 2025 | Emil D Kakkis President & CEO | SOpen-market sale Common Stock10b5-1 | -73,434 | $42.10 | $3.1M | 641,731 | Mar 4, 2025 |
| Mar 1, 2025 | Dennis Karl Huang See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +26,074 | $0.00 | $0 | 26,074 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore Alan Huizenga SVP, Chief Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +5,632 | $0.00 | $0 | 5,632 | Mar 4, 2025 |
| Mar 1, 2025 | Erik Harris EVP & Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +30,246 | $0.00 | $0 | 30,246 | Mar 4, 2025 |
| Mar 1, 2025 | Eric Crombez EVP and Chief Medical Officer | AGrant or award Stock Ooption (Right to Buy)derivative | +30,246 | $0.00 | $0 | 30,246 | Mar 4, 2025 |
| Feb 28, 2025 | Emil D Kakkis President & CEO | SOpen-market sale Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -25,000 | $42.48 | $1.1M | 2,158,985 | Mar 4, 2025 |
| Mar 1, 2025 | Emil D Kakkis President & CEO | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +78,448 | $0.00 | $0 | 78,448 | Mar 4, 2025 |
| Dec 30, 2024 | Emil D Kakkis President & CEO | SOpen-market sale Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -11,727 | $42.23 | $495k | 2,183,985 | Dec 31, 2024 |
| Dec 10, 2024 | Theodore Alan Huizenga SVP, Chief Accounting Officer | GGift Common Stock | -648 | $0.00 | $0 | 41,840 | Dec 11, 2024 |
| Dec 9, 2024 | Emil D Kakkis President & CEO | GGift Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -20,000 | $0.00 | $0 | 2,203,985 | Dec 11, 2024 |
| Dec 10, 2024 | Emil D Kakkis President & CEO | SOpen-market sale Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -8,273 | $50.00 | $414k | 2,195,712 | Dec 11, 2024 |
| Oct 10, 2024 | Howard Horn Chief Financial Officer | SOpen-market sale Common Stock | -7,465 | $52.76 | $394k | 92,301 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eric CrombezEVP and Chief Medical Officer
- Deborah Dunsiredirector
- Matthew K Fustdirector
- Erik HarrisEVP & Chief Commercial Officer
- Howard HornChief Financial Officer
- Dennis Karl HuangSee Remarks
- Theodore Alan HuizengaSVP, Chief Accounting Officer
- Emil D KakkisPresident & CEO
- Thomas Richard KassbergCBO & EVP
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.